Description
Key facts
Detection method:Colorimetric,
Sample types:Plasma, Serum,
Reacts with:Mouse, Rat, Human, Pig, Monkey, Horse,
Assay type:Sandwich (quantitative),
Sensitivity:= 0.11 ng/mL,
Range:0.281 - 18 ng/mL,
Assay time:4h,
Assay Platform:Pre-coated microplate (12 x 8 well strips)
Product details:
Glucagon-Like Peptide 2 ELISA Kit ab222863 is a sandwich ELISA to measure Glucagon-Like Peptide 2 in serum, plasma with a sensitivity of 0.11 ng/ml.
How the assay works
The kit has been validated using rat, human, swine, and monkey samples. This assay employs a quantitative sandwich enzyme immunoassay technique, which measures GLP-2 in approximately 4 hours. A polyclonal antibody specific for GLP-2 has been pre-coated onto a 96-well microplate with removable strips. GLP-2 in standards and samples is sandwiched by the immobilized antibody and biotinylated polyclonal antibody specific for GLP-2, which is recognized by a streptavidin-peroxidase conjugate. All unbound material is washed away and a peroxidase enzyme substrate is added. The color development is stopped and the intensity of the color is measured.
The entire kit may be stored at -20°C for long term storage before reconstitution - Avoid repeated freeze-thaw cycles.
Assay Specificity
Our ELISA kits are rigorously validated to ensure the highest level of consistency and reproducibility. Please check the protocol booklet for more details
Glucagon-Like Peptide 2 ELISA Kit ab222863 protocol summary
1. Add standard or sample to appropriate wells. Incubate at room temperature
2. Wash and add prepared biotin antibody to each well. Incubate at room temperature.
3. Wash and add prepared Streptavidin-Peroxidase Conjugate. Incubate at room temperature
4. Add Chromogen Substrate to each well. Incubate at room temperature
5. Add Stop Solution to each well. Read at 450 nm immediately.
Glucagon-like peptide 2 (GLP-2) is a thirty-three amino acid peptide that is secreted by intestinal endocrine cells alongside GLP-1. GLP-2 and GLP-1 are co-secreted from enteroendocrine L-cells located in distal intestine in response to enteral nutrient ingestion, particularly fats and carbohydrates. GLP-2 secretion is mediated by direct nutrient stimulation of the L-cells and indirect action from enteroendocrine and neural inputs. GLP-2 acts to enhance nutrient absorption by inhibiting gastric motility and secretion and by stimulating nutrient transport.
Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions-Multi, Storage information-Please refer to protocols
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Glucagon-like peptide 2 (GLP2) also known as glucagon-like peptide-2 and GLP-2 is a peptide that is derived from the proglucagon gene and weighs approximately 4.2 kDa. It is expressed mostly in the intestinal mucosa particularly in the L-cells of the ileum and colon. GLP2 is a 33-amino-acid peptide hormone that is secreted in response to nutrient intake. This peptide is involved in various bodily functions acting mainly in the gastrointestinal tract.
Biological function summary
GLP2 functions to enhance intestinal growth and nutrient absorption. It promotes mucosal epithelial growth increases villus height and reduces gut permeability. These actions make GLP2 critical for maintaining the structural and functional integrity of the gastrointestinal tract. It operates independently and is not part of a larger protein complex but works alongside similar hormones for gut homeostasis.
Pathways
GLP2 is involved in the enteroendocrine signaling pathway. This includes the modulation of the GLP2 receptor which impacts intestinal growth and function. The peptide also shows interplay with proteins like glucagon-like peptide 1 (GLP1) as both affect energy balance and glucose homeostasis although through different mechanisms. GLP2's primary role in enhancing nutrient absorption complements GLP1's efforts in glucose regulation.
GLP2's link to short bowel syndrome and inflammatory bowel disease highlights its therapeutic potential. Its ability to improve intestinal adaptation and reduce inflammation positions GLP2 as a candidate for treating these conditions. Additionally a connection exists with glucagon-like peptide 1 (GLP1) due to their common origin and overlapping pathways although each has distinct functions and disease relevance.
